Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 18/20 | 0.50 |
| ▸ | MAS1 | P04201 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23120789 | 1.00 | AGTR2 (0.50) | AGTR2MAS1AGTR1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL23120715 | 0.96 | AGTR2 (0.47) | AGTR2MAS1CYP3A4 | |
| SCHEMBL23121204 | 0.90 | AGTR2 (0.54) | AGTR2AGTR1CYP3A4 | |
| SCHEMBL29700607 | 0.90 | AGTR2 (0.54) | AGTR2AGTR1CYP3A4 | |
| SCHEMBL27081932 | 0.89 | AGTR2 (0.54) | AGTR2MAS1AGTR1CYP3A4 | |
| SCHEMBL25248583 | 0.88 | AGTR2 (0.55) | AGTR2CYP3A4 | |
| SCHEMBL29047252 | 0.88 | AGTR2 (0.57) | AGTR2AGTR1 | |
| SCHEMBL29700575 | 0.88 | AGTR2 (0.52) | AGTR2MAS1AGTR1CYP3A4 | |
| SCHEMBL23121148 | 0.88 | AGTR2 (0.52) | AGTR2MAS1AGTR1CYP3A4 | |
| SCHEMBL23120747 | 0.88 | AGTR2 (0.50) | AGTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | claimed |
| US-12435072-B2 | Compounds | VICORE PHARMA AB (SE) | 2025-10-07 | — | — | US | disclosed |
| US-20220388994-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2022-12-08 | — | — | US | disclosed |
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388994-A1 | NEW COMPOUNDS | RXFP3, RXFP4, RXFP1 | AGTR2 110/4885MAS1 538/4885AGTR1 62/4885 |
| US-12435072-B2 | Compounds | RXFP3, RXFP4, ARG1 | AGTR2 94/4885MAS1 657/4885AGTR1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.